Istanbul, Turkey, 15th September 2009 – Further evidence of the superior antidepressant efficacy of Valdoxan®/Thymanax® (agomelatine) over conventional selective serotonin reuptake inhibitors (SSRIs) and serotonin noradrenalin reuptake inhibitor (SNRI) antidepressants was presented today at the Servier satellite symposium on the occasion of the 22nd European College of Neuropsychopharmacology (ECNP) Congress, with educational financial support provided [...]

Valdoxan’s antidepressant efficacy has been demonstrated in a large clinical program including 5 800 patients of whom 3 900 were treated with Valdoxan. The short-term efficacy of Valdoxan has been demonstrated over treatment periods of 6 to 12 weeks using standardized scales (Hamilton Depression Rating Scale [HAMD], Montgomery and Asberg Depression Rating Scale [MADRS], Clinical [...]

Valdoxan’s onset of efficacy has been reported and measured on the Clinical Global Impression-Improvement [CGI-I] scale and Visual Analog Scales [VAS]as early as the first week of treatment. From the first week of treatment, Valdoxan demonstrated to provide significant efficacy in terms of CGI score improvement, as well as VAS score improvement.
Significant improvement in CGI [...]